<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639701</url>
  </required_header>
  <id_info>
    <org_study_id>AAAQ7552</org_study_id>
    <nct_id>NCT03639701</nct_id>
  </id_info>
  <brief_title>Treatment of TK2 Deficiency With Thymidine and Deoxycytidine</brief_title>
  <official_title>Deoxythymidine and Deoxycytidine Treatment for Thymidine Kinase 2 (TK2) Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Muscular Dystrophy Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario 12 de Octubre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Seville</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council Mitochondrial Biology Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro de Investigación Biomédica en Red Enfermedades Raras (CIBERER), Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospitales Universitarios Virgen del Rocío</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with confirmed mitochondrial DNA depletion syndrome 2 (thymidine kinase 2 [TK2]
      deficiency) have reduced levels of nucleotides (deoxythymidine monophosphate and
      deoxycytidine monophosphate) for mitochondrial DNA synthesis. This results in mitochondrial
      DNA depletion syndrome (i.e less number of functional mitochondrial DNA). Patients with
      confirmed TK2 deficiency will be treated with open label deoxythymidine (dThd) and
      deoxycytidine (dCyt), which are nucleotide precursors, with the expectation that the cells
      could make additional mitochondrial DNA. This in turn may help reduce the clinical symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mitochondrial are responsible for the production of cellular energy. Mitochondria contain DNA
      which is the encoding system ( &quot;recipe&quot;) for making the proteins that allow the mitochondria
      to function. Reduced amount of mitochondrial DNA, caused by genetic mutations in certain
      genes, Mitochondrial DNA Depletion Syndrome. This can result in symptoms; such as fatigue,
      weakness, and deficiencies in various body systems. TK2 deficiency is considered a
      mitochondrial depletion syndrome. Patients with TK2 deficiency have weakness and walking
      difficulty. They also have depleted levels of chemicals (phosphorylated deoxythymidine and
      deoxycytidine) used to make mitochondrial DNA. Based on previous studies with a similar
      compound, patients reported more energy and better motor skills.

      Eligible patients include those with genetic mutations in the TK2 gene who are willing to
      attend several outpatient visits, and have motor skills testing, neurological exam by doctor,
      and blood samples.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 16, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label treatment with thymidine and deoxycytidine</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alanine aminotransferase</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Number of participants with treatment-related elevated alanine aminotransferase (ALT) serum level relative to upper limit of normal (expressed as ratios) grade 3 or higher as defined by CTCAE 4.03.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate aminotransferase</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Number of participants with treatment-related elevated aspartate aminotransferase (AST) serum level relative to upper limit of normal (expressed as ratios) grade 3 or higher as defined by CTCAE 4.03.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gamma-glutamyltransferase</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Number of participants with treatment-related elevated gamma-glutamyltransferase (GGT) serum level relative to upper limit of normal (expressed as ratios) grade 3 or higher as defined by CTCAE 4.03.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood lymphocyte count</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Blood lymphocyte count increased relative to upper limit or normal or decreased relative to lower limit of normal (expressed as ratios) grade 3 or higher as defined by CTCAE 4.03.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Creatinine</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Serum creatinine level increased relative to upper limit of normal (expressed as ratios) grade 3 or higher as defined by CTCAE 4.03.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Number of patients with treatment related electrocardiogram (ECG) QT corrected interval (QTc) grade 3 or higher as defined by CTCAE version 4.03.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diarrhea</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Patient-Reported Outcome Measurement Information System (PROMIS) Scale v1.0 - Gastrointestinal Diarrhea 6a score (score range 0-30 with higher scores indicating more severe diarrhea)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Time to mechanical ventilation, death, or both will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk test</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Distance walked in meters over 6 minutes will be measured in ambulatory patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) score (0-64 point range with higher scores indicating better function) will be assessed in infants to assess motor function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hammersmith Functional Motor Scale Expanded (HFMSE)</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Hammersmith Functional Motor Scale Expanded (HFMSE) score (0-66 point range with higher scores indicating better function) will be measured in subjects &gt;1 year-old.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Capacity</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Vital capacity (percent of predicted normal based on age and height) will be measure by spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time on Mechanical Ventilation</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Number of hours per day that subjects use mechanical ventilation will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>euro Quality of Life (Neuro-QoL) in adults</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Neuro Quality of Life (Neuro-QoL) short forms will be used to assess effects of muscle weakness on motor function and activities of daily living. In adults, Lower and Upper Extremity scales will be assessed (0-80 points with higher scores indicating better function).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuro Quality of Life (Neuro-QoL) in pediatric subjects</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Neuro Quality of Life (Neuro-QoL) forms will be used to assess effects of muscle weakness on motor function and activities of daily living. In pediatric subjects (&lt;18 years-old), Lower and Upper Extremity scales will be assessed (0-160 points with higher scores indicating better function).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suicidal Ideation</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Suicidal ideation will be assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS), which contains 6 &quot;yes&quot; or &quot;no&quot; questions. Answer of &quot;yes&quot; to any question indicates possible suicide risk and answer of &quot;yes: to questions 4, 5, or 6 indicates high-risk.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Mitochondrial DNA Depletion Syndrome 2 Myopathic Type</condition>
  <condition>Thymidine Kinase 2 Deficiency</condition>
  <arm_group>
    <arm_group_label>Open label thymidine and deoxycytidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive open label thymidine and deoxycytidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymidine</intervention_name>
    <description>Mitochondrial DNA nucleotide precursors. Dose escalation: 130mg/kg/day x 14 days, 260 mg/kg/day x 14 days, and 400mg/kg/day as tolerated. Compounds are taken orally and divided into 3 doses daily.</description>
    <arm_group_label>Open label thymidine and deoxycytidine</arm_group_label>
    <other_name>Deoxycytidine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Genetically confirmed diagnosis of TK2 deficiency

          -  Deemed by principle investigator to be symptomatic with TK2 deficiency

          -  Single gene disease; absence of polygenic disease

          -  Hematocrit within normal range for age group

          -  Patient or patient's guardian able to consent and comply with protocol requirements

          -  Presence of caregiver to ensure study compliance (if needed)

          -  Abstention from use of all pill-form dietary supplements and non-prescribed
             medications (except as allowed by the investigator)

          -  Abstention from use of other investigational medications or other medications
             according to the study investigator

        Exclusion Criteria:

          -  Clinical history of bleeding or abnormal prothrombin time (PT)/partial thromboplastin
             time (PTT)

          -  Hepatic insufficiency with liver function tests (LFTs) greater than two times normal

          -  Renal insufficiency requiring dialysis

          -  Any other concurrent inborn errors of metabolism

          -  Severe end-organ hypo-perfusion syndrome secondary to cardiac failure resulting in
             lactic acidosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michio Hirano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Garone C, Taylor RW, Nascimento A, Poulton J, Fratter C, Domínguez-González C, Evans JC, Loos M, Isohanni P, Suomalainen A, Ram D, Hughes MI, McFarland R, Barca E, Lopez Gomez C, Jayawant S, Thomas ND, Manzur AY, Kleinsteuber K, Martin MA, Kerr T, Gorman GS, Sommerville EW, Chinnery PF, Hofer M, Karch C, Ralph J, Cámara Y, Madruga-Garrido M, Domínguez-Carral J, Ortez C, Emperador S, Montoya J, Chakrapani A, Kriger JF, Schoenaker R, Levin B, Thompson JLP, Long Y, Rahman S, Donati MA, DiMauro S, Hirano M. Retrospective natural history of thymidine kinase 2 deficiency. J Med Genet. 2018 Aug;55(8):515-521. doi: 10.1136/jmedgenet-2017-105012. Epub 2018 Mar 30.</citation>
    <PMID>29602790</PMID>
  </results_reference>
  <results_reference>
    <citation>Lopez-Gomez C, Levy RJ, Sanchez-Quintero MJ, Juanola-Falgarona M, Barca E, Garcia-Diaz B, Tadesse S, Garone C, Hirano M. Deoxycytidine and Deoxythymidine Treatment for Thymidine Kinase 2 Deficiency. Ann Neurol. 2017 May;81(5):641-652. doi: 10.1002/ana.24922. Epub 2017 May 4.</citation>
    <PMID>28318037</PMID>
  </results_reference>
  <results_reference>
    <citation>Garone C, Garcia-Diaz B, Emmanuele V, Lopez LC, Tadesse S, Akman HO, Tanji K, Quinzii CM, Hirano M. Deoxypyrimidine monophosphate bypass therapy for thymidine kinase 2 deficiency. EMBO Mol Med. 2014 Aug;6(8):1016-27. doi: 10.15252/emmm.201404092.</citation>
    <PMID>24968719</PMID>
  </results_reference>
  <results_reference>
    <citation>Chanprasert S, Wang J, Weng SW, Enns GM, Boué DR, Wong BL, Mendell JR, Perry DA, Sahenk Z, Craigen WJ, Alcala FJ, Pascual JM, Melancon S, Zhang VW, Scaglia F, Wong LJ. Molecular and clinical characterization of the myopathic form of mitochondrial DNA depletion syndrome caused by mutations in the thymidine kinase (TK2) gene. Mol Genet Metab. 2013 Sep-Oct;110(1-2):153-61. doi: 10.1016/j.ymgme.2013.07.009. Epub 2013 Jul 17.</citation>
    <PMID>23932787</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 7, 2018</study_first_submitted>
  <study_first_submitted_qc>August 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>August 1, 2019</last_update_submitted>
  <last_update_submitted_qc>August 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Michio Hirano, MD</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Thymidine</keyword>
  <keyword>Deoxycytidine</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Since there are very few patients in the world with TK2 Deficiency, we may share de-identified data with other researchers who are treating patients with TK2 Deficiency</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

